• Tanveer Mir, Yasar Sattar, Hassan Bin Attique, Tanveer Hussain, M Chadi Alraies, Mujeeb Sheikh, and Waqas T Qureshi.
• Internal Medicine, Detroit Medical Center, Wayne State University. Detroit, MI, USA.
• Cardiovasc Revasc Med. 2021 Mar 9.

BackgroundThe use of direct oral anticoagulants (DOAC) in preference to vitamin K antagonists (VKA) as a treatment of left ventricle (LV) thrombus is controversial.MethodsLiterature search for full-text articles and conference abstracts was performed using PubMed, EMBASE databases search was performed to identify articles that compared use of DOAC vs. VKA in patients with LV thrombus. The primary outcome was composite failure or adverse effects of DOAC and VKA. Other outcomes were resolution of thrombus, systemic thromboembolism, major bleeding, and mortality. Pooled odds ratio (OR) with 95% confidence interval (CI) were computed using random effects model.ResultsSeven studies with 1003 patients (mean age DOAC = 58.8 years and VKA = 58.9 year, 55.5% males) were included in this study. There were 306 (30.5%) patients that were treated with DOAC and 697 (69.5%) patients were treated with VKA. Overall, there were no significant differences between both agents in terms of composite failure/adverse effects, resolution of thrombus, systemic embolism, major bleeding, or mortality.ConclusionIn this pooled analysis, outcomes in patients on DOAC were comparable to VKA. The hypothesis generated could suggest DOAC could be used interchangeably with VKA in patients with LV thrombus. Randomized trials are needed for generalization of results.Copyright © 2021 Elsevier Inc. All rights reserved.

5 keywords...

hide…